Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Insulin Delivery, Other Feb 10 | 2020Zealand to Acquire Valeritas; vTv Positive Ph2 Data for TTP399 in T1DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist Feb 06 | 2020Novo Q4 '19 London Earnings; Sanofi and BD Q4 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist Feb 05 | 2020Tirzepatide CVOT Record Available on CT.govPurchase Blast
$599
Posted in: DPP-IVi, SGLT2i Feb 05 | 2020Merck Keeps Januvia As it Spins Off Other Legacy BrandsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon Feb 05 | 2020Positive Topline Novo QW Insulin Results; Novo Q4 '19 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 03 | 2020Dexcom Non-intensive G6 CGM Updated Approval; Dexcom G5 Receiver Recall; FDA Concludes MET NDMA Impurity InvestigationPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA Jan 31 | 2020Rybelsus and URLi Receive Positive CHMP OpinionsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 31 | 2020Thoughts on New CVS Program to Eliminate Diabetes Drug OOP CostsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, SGLT2i Jan 30 | 2020Lilly and Roche Q4 '19 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jan 28 | 2020Lilly to Donate Insulin Pens; Fractyl Launches Revita DMR in the UKPurchase Blast
$599
Posted in: DPP-IVi, SGLT2i Jan 28 | 2020Trijardy XR (empa/lina/met XR FDC) Approved; Trijardy Label and Market AnalysisPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, SGLT2i Jan 27 | 2020Oral Semaglutide and URLi CHMP Opinions Anticipated; Forxiga Lower-limb Warning?; Xeris Gvoke Filed (CHMP Agenda January 27-30)Purchase Blast
$599
Posted in: Glucose Monitoring Jan 27 | 2020i-SENS Receives FDA Clearance for Another BT BGMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jan 25 | 2020Biocon/Mylan Bs-Glargine PDUFA in June 2020; Biocon CY Q4 '19 (FY Q3 '20) Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, SGLT2i Jan 22 | 2020New G&L Bs-Glargine Ph1 Trial to Support Approval; J&J and Abbott Q4 '19 Earnings Updates; New Medtronic AHCL Study; Biocon Generic Dapa Tentatively Approved by FDAPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring Jan 21 | 2020New i-SENS BT BGM 510(k) Clearance; Integrity Non-invasive Glucose Meter CE Mark; Livongo Available to Horizon BCBS NJ; Jay Skyler Joins Oramed Advisory BoardPurchase Blast
$599
Posted in: GLP-1RA Jan 17 | 2020Thoughts on Ozempic CV Indication and Rybelsus Data-on-labelPurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i Jan 16 | 2020JPM 2020 Day 4: Lexicon and Hanmi; Generic Jardiance Tentative ApprovalPurchase Blast$599
Posted in: Insulin Delivery, Other Jan 15 | 2020JPM 2020 Day 3: No Diabetes Webcasts; Tandem Launches Control IQ; ADA Endorses Drug Affordability BillsPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
